FMP

FMP

Enter

GKTX.PA - Genkyotex SA

Profile of Genkyotex SA(GKTX.PA), Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform

About

ceo

Mr. Ilias Papatheodorou

sector

Healthcare

industry

Biotechnology

website

http://www.genkyotex.com

exchange

EURONEXT

Description

Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Labège, France.

CIK

N/A

ISIN

FR0013399474

CUSIP

F4373W104

Address

516 rue Pierre Et Marie Curie

Phone

33561287060

Country

FR

Employee

9

IPO Date

Apr 4, 2014

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep